Related Experiment Video
Updated: Aug 20, 2026

Genetic Study of Axon Regeneration with Cultured Adult Dorsal Root Ganglion Neurons
Published on: August 17, 2012
Expression of GDNF in spinal cord injury and its repression by ONO-1714
Shojiro Nakashima1, Yukihiro Matsuyama, Yimin Yu
1Department of Orthopaedic Surgery, Nagoya University School of Medicine, 65 Tsuruma-cho, Showa-ku, Nagoya, 466-8550, Japan. shojiro@med.nagoya-u.ac.jp
Abstract:
ONO-1714 is a newly developed specific inhibitor for inducible nitric oxide synthase (iNOS). We have shown that ONO-1714 has some neuroprotective effects. In this report, we investigated the effects of ONO-1714 in injured spinal cords, and analyzed the expression of glial cell-line-derived neurotrophic factor (GDNF) after injury. Male Sprague-Dawley rats were subjected to contusive spinal cord injury and administrated 0.1 mg/kg ONO-1714. The injured spinal cords were isolated at appropriate time points and GDNF mRNA was determined by semi-quantitative RT-PCR. GDNF-positive cells were also counted after immunohistochemical stainings. ONO-1714 diminished the early stage production of GDNF after injury as well as it reduced the production of nitric oxide produced by iNOS and apoptotic cells.
Insights
The study shows that ONO-1714, an inducible nitric oxide synthase (iNOS) inhibitor, reduces glial cell-line-derived neurotrophic factor (GDNF) and nitric oxide production following spinal cord injury in rats.
Area of Science:
- Neuroscience
- Pharmacology
Background:
- Inducible nitric oxide synthase (iNOS) plays a role in spinal cord injury.
- Glial cell-line-derived neurotrophic factor (GDNF) expression is altered after spinal cord injury.
- ONO-1714 is a specific inhibitor of iNOS with known neuroprotective effects.
Purpose of the Study:
- To investigate the effects of ONO-1714 on spinal cord injury.
- To analyze the expression of GDNF following spinal cord injury in the presence of ONO-1714.
Main Methods:
- Male Sprague-Dawley rats underwent contusive spinal cord injury.
- Administration of 0.1 mg/kg ONO-1714 post-injury.
- Analysis of GDNF mRNA via semi-quantitative RT-PCR.
- Quantification of GDNF-positive cells using immunohistochemistry.
Main Results:
- ONO-1714 diminished early-stage GDNF production after spinal cord injury.
- ONO-1714 reduced nitric oxide production mediated by iNOS.
- Apoptotic cell count was reduced following ONO-1714 administration.
Conclusions:
- ONO-1714 impacts GDNF expression and iNOS activity post-spinal cord injury.
- The findings suggest a potential therapeutic role for ONO-1714 in managing spinal cord injury by modulating inflammatory and neurotrophic responses.
